Free tool
Drug Search
Every brand-name drug and biologic application (NDA or BLA) in Drugs@FDA: 5,899 in all. Generic (ANDA) applications are not listed; their reference drug is.
Last checked: Nov 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
4 matches for "Rigel Pharms"
Brand names that start with your search come first, then marketed and novel drugs.
| Drug | Sponsor | Application | First approved | Programs |
|---|---|---|---|---|
| Gavreto Pralsetinib | Rigel Pharms | NDA213721 | Sep 4, 2020 | NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan |
| Veppanu Vepdegestrant | Rigel Pharms | NDA219835 | May 1, 2026 | Novel |
| Tavalisse Fostamatinib Disodium | Rigel Pharms | NDA209299 | Apr 17, 2018 | NovelOrphan |
| Rezlidhia Olutasidenib | Rigel Pharms | NDA215814 | Dec 1, 2022 | NovelOrphan |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.